Stocktoria
Arbutus Biopharma Corp ABUS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-11-13
Arbutus Biopharma Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| Net margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% |
| FCF margin | -281.5% | -1053.8% | -479.3% | -91.9% | -622.0% |
| Return on assets | -35.4% | -53.1% | -50.4% | -35.5% | -37.3% |
| Return on equity | -43.7% | -71.8% | -68.7% | -50.8% | -45.0% |
| Debt / equity | 0.00× | 0.00× | 0.00× | 0.00× | 0.00× |
| Current ratio | 15.73 | 8.15 | 5.87 | 4.60 | 14.32 |
| Revenue growth | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% |
Source: SEC EDGAR filings · CIK 0001447028 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.